YOLFTbeta
47

Tomocube Inc

475960 · KQ · Healthcare / Biotechnology

25,400.00KRW-3050.00 (-10.72%)

Price History

Full chart

Market Stats

Previous Close28,450.00
Open28,350.00
Day Range24,500.00 – 29,350.00
52-Week Range26,000.00 – 67,800.00
Volume139.05K
Market Cap459.05B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
50-Day Avg31,448.00
200-Day Avg44,366.75

About

Tomocube, Inc. engages in the manufacture and sale of optical devices and medical equipment. Its holotomography (HT) products include HT-X1 for live-cell imaging and analysis; and HT-2H for 3D live cell imaging. The company also offers TomoAnalysis, a 3D image visualization and analysis software. In addition, it provides accessories, such as HT-ready 96 well plates; TomoDish that is designed to accommodate both adherent and suspension cells; TomoChamber, a stage-top incubator designed for long-term live cell imaging; TomoPlate, an active vibration isolation system that enables users to capture images in a stable environment; and vessel holders, environmental controllers, and 3D controllers. The company was founded in 2015 and is headquartered in Daejeon, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Park Yongkeun
  • Employees65
  • Headquarters155, Sinseong-ro, Daejeon, South Korea, 34109, Korea
  • Websitehttps://www.tomocube.com

Leadership

  • Dr. Park YongkeunChief Executive Officer
  • Mr. Wansung KuCFO & Chief Strategy Officer
  • Mr. Ko Sung HoChief Operation Officer
  • Mr. Taehong KimSenior Vice President of Precision Division
  • Ms. Sumin LeeSenior Vice President of Life Science Division

Financials

Income Statement

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.63B1.87B3.75B5.94B11.31B
Growth (%)-+15.12%+100.28%+58.48%+90.39%
Cost of Revenue959.09M928.36M1.57B2.35B3.86B
Gross Profit666.12M942.67M2.18B3.59B7.44B
Gross Margin40.99%50.38%58.23%60.45%65.82%
Operating Expense7.08B7.31B8.91B12.37B13.01B
Operating Income-6.41B-6.37B-6.73B-8.78B-5.57B
Operating Margin-394.42%-340.41%-179.48%-147.84%-49.25%
EBITDA-34.39B-17.31B-7.01B-3.22B
EBITDA Margin-1838.10%-461.85%-117.97%-28.52%
Net Income-19.35B29.34B-23.55B-8.30B-4.81B
Net Income Margin-1190.54%1567.93%-628.46%-139.80%-42.54%
R&D3.77B3.24B3.67B5.47B5.22B
R&D as % of Total Revenue232.18%173.34%97.88%92.17%46.19%
Interest Expense2.77B4.34B5.12B65.85M72.18M
Interest Expense % of Total Revenue170.57%232.00%136.66%1.11%0.64%

Balance Sheet

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets29.96B25.06B19.77B43.61B41.51B
Total Liabilities88.24B52.89B2.07B1.62B2.72B
Total Equity-58.27B-27.83B17.71B41.99B38.79B
Cash18.18B1.53B2.85B12.69B11.45B

Cash Flow

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.42B-6.75B-5.93B-6.54B-6.75B
Investing Cash Flow--9.77B7.47B-14.40B-
Financing Cash Flow--156.61M-182.19M30.68B-
Capital Expenditure645.64M568.86M231.50M934.29M773.57M
Free Cash Flow-5.07B-7.32B-6.16B-7.47B-7.53B
FCF to OCF114.61%108.43%103.90%114.29%111.45%

Earnings

Report DateMar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------
EPS Actual-865.98-85.94-116.0748.28-101.33-15.16
Surprise------
Timing------

Key Statistics & Ratios

Market Cap459.05B
Enterprise Value345.25B
Trailing P/E0.00
Forward P/E0.00
Price / Sales30.16
Price / Book9.86
Revenue (TTM)15.22B
Gross Profit (TTM)9.80B
EBITDA-2.26B
Profit Margin-16.11%
Operating Margin-11.82%
Return on Equity-6.42%
Return on Assets-5.85%
Shares Outstanding13.38M
Shares Float8.19M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%